Lonza (in our Long Portfolio) has released H1 17 numbers. Sales reached CHF2,323m (+15.1%), EBITDA CHF529m (+19.4%), EBIT CHF373m (+27.7%), and net profit CHF233m (+20.1%). Net debt reached CHF1,588m vs CHF1505m a year before. Note these numbers exclude Capsugel, which will be consolidated over H2. The group also presented its mid-term guidance to 2022: sales of CHF7.5bn, a core EBITDA of 30% (CHF2.25bn) and core RONOA of 35% (CHF2.63bn), which of course includes Capsugel.
26 Jul 2017
Great H1 17 and more to come with the integration of Capsugel!
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Great H1 17 and more to come with the integration of Capsugel!
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
26 Jul 2017 -
Author:
Fabrice Farigoule -
Pages:
3
Lonza (in our Long Portfolio) has released H1 17 numbers. Sales reached CHF2,323m (+15.1%), EBITDA CHF529m (+19.4%), EBIT CHF373m (+27.7%), and net profit CHF233m (+20.1%). Net debt reached CHF1,588m vs CHF1505m a year before. Note these numbers exclude Capsugel, which will be consolidated over H2. The group also presented its mid-term guidance to 2022: sales of CHF7.5bn, a core EBITDA of 30% (CHF2.25bn) and core RONOA of 35% (CHF2.63bn), which of course includes Capsugel.